Kalaris Therapeutics, Inc. (KLRS) stock
Close on Nov 12, 2026Market cap $39.52MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026
Valuation
- Market cap
- $39.52M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.83
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$43.40M
- EPS, diluted
- -$2.85
- Free cash flow
- -$38.57M
- Book value per share
- $1.99
- Diluted shares
- 24M
Trading
- Next earnings
- Mar 16, 2027 (estimated, before the open)
- Previous close
- $1.90
- Open
- $1.93
- Day's range
- $1.65 – $1.95
- Volume
- 200,281
- Average volume (20 days)
- 83,376
- Beta (5 years)
- 1.29
- 52-week range
- $1.65 – $11.88
- RSI (14 days)
- 33.3
- Volatility (1 year)
- 89.0%
- Relative volume
- 1.00×
- WACC
- 11.3%
Market cap history
Month-end market cap since 2020, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | KLRS | S&P 500 | Difference | KLRS per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -26.5% | -2.7% | −23.9 pts | ||
| 3 months | -57.9% | -1.7% | −56.1 pts | ||
| Year to date | -80.3% | +11.9% | −92.2 pts | ||
| 1 year | -66.5% | +12.0% | −78.5 pts | ||
| 3 years | -94.9% | +78.2% | −173.1 pts | -63.0% | +21.2% |
| 5 years | -99.7% | +73.2% | −172.9 pts | -68.2% | +11.6% |
| 10 years | -87.3% | +309.6% | −397.0 pts | -18.7% | +15.1% |
Eight years at a glance
Fiscal years 2018 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Kalaris Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Update
- Update
- Results
- Results
About Kalaris Therapeutics
Biological Products, (No Diagnostic Substances)
The company is a clinical-stage biopharmaceutical business focused on developing and commercializing therapeutics for prevalent retinal diseases characterized by substantial unmet medical needs. Its development pipeline centers on treatments for neovascular and exudative eye disorders, specifically neovascular age-related macular degeneration, diabetic macular edema, diabetic retinopathy, and retinal vein occlusion. Its primary product candidate is TH103, an intravitreally administered anti-vascular endothelial growth factor recombinant fusion protein engineered to enhance intraocular retention and improve durability over existing therapies. Because the company remains in the clinical investigation stage, it currently has no commercialized treatments and primarily directs its clinical efforts toward patients suffering from vision-threatening ocular conditions.
Company profile, executives and historyKalaris Therapeutics stock: common questions
What is Kalaris Therapeutics's stock price?
KLRS closed at $1.66 on Nov 12, 2026, down 12.63% on the day. Over the past 52 weeks it traded between $1.65 and $11.88.
What is Kalaris Therapeutics's market cap?
Kalaris Therapeutics was worth $39.52M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is KLRS's P/E ratio?
Kalaris Therapeutics lost money over fiscal 2025 (diluted EPS -$2.85), so it has no meaningful P/E ratio.
Does Kalaris Therapeutics pay a dividend?
No. Kalaris Therapeutics has not paid a cash dividend over the last twelve months.
When does Kalaris Therapeutics report earnings next?
Kalaris Therapeutics is expected to report Q4 FY2026 results on Mar 16, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has KLRS stock performed over the past year?
Including dividends, KLRS returned -66.5% over the past year, against +12.0% for the S&P 500.
Who are Kalaris Therapeutics's competitors?
Companies most similar to Kalaris Therapeutics by business, industry and size include OTLK, KOD, OKYO, TARS, RLAY.
See a number that looks wrong?